Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 1, 2019. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. It solely discloses the current status of issued share capital and treasury shares as of February 28, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risks, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Important Facts for Investors
- Issued Share Capital: As of February 28, 2019, the Company had 5,380,994,285 Ordinary Shares of 25 pence each.
- Treasury Shares: 414,605,950 Ordinary Shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,966,388,335.
- Regulatory Use: This voting rights figure is the required denominator for shareholders to determine if they must notify the market of their interest or changes thereto.